Keywords
Anafilaxia
Vacunación
Abstract
Even though the SARS-CoV-2 pandemic represents a historical challenge, science has had an exponential development, and the current vaccination campaigns are proof of this. Unfortunately, along came misinformation and myths regarding their production and their adverse effects. For this reason, we have considered of utter importance to review anaphylaxis, one of the most feared vaccine adverse events.Anaphylaxis can be defined as a life-threatening acute and systemic allergic reaction, with a wide clinical spectrum, which can be explained by many immunological mechanisms, and whose diagnostic complexity demands the fulfillment of strict criteria. Though infrequent, any vaccine has the potential to trigger anaphylaxis. In the United States, for the new SARS-CoV-2 vaccines, rates from 1:200 000 (Pfizer-BioNTech) to 1:360 000 doses (Moderna) have been estimated. Vaccine adverse events can be mediated by hypersensitivity reactions, either allergic or not. Unlike a typical drug allergy, rarely is the active ingredient responsible for the reaction. Therefore, excipients must be considered during the approach to this problem. Vaccine associated anaphylaxis has to be referred to an allergist so as to guarantee the maximum benefit for the patient and improve the vaccines’ security profile.
References
Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J. Vaccine hesitancy: an overview. Hum Vaccin Immunother. 2013;9(8):1763-73. DOI: 10.4161/hv.24657
Ruiter RA, Kessels LT, Peters GJ, Kok G. Sixty years of fear appeal research: current state of the evidence. Int J Psychol. 2014;49(2):63-70. DOI: 10.1002/ijop.12042
Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, El-Gamal Y, et al. COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J. 2021;14(2):100517. DOI: 10.1016/j.waojou.2021.100517
Shaker MS, Wallace DV, Golden DBK, Oppenheimer J, Bernstein JA, Campbell RL, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020;145(4):1082-123. DOI: 10.1016/j.jaci.2020.01.017
Kohl KS, Gidudu J, Bonhoeffer J, Braun MM, Buettcher M, Chen RT, et al. The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine. 2007;25(31):5671-4. DOI: 10.1016/j.vaccine.2007.02.063
Vanlander A, Hoppenbrouwers K. Anaphylaxis after vaccination of children: review of literature and recommendations for vaccination in child and school health services in Belgium. Vaccine. 2014;32(26):3147-54. DOI: 10.1016/j.vaccine.2014.03.096.
McNeil MM. Vaccine-Associated Anaphylaxis. Curr Treat Options Allergy. 2019;6(3):297-308. DOI: 10.1007/s40521-019-00215-0
Bohlke K, Davis RL, Marcy ; SM, Braun ; MM, Destefano F, Black SB, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112(4):815-20. DOI: 10.1542/peds.112.4.815
McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):868-78. DOI: 10.1016/j.jaci.2015.07.048
Dreskin SC, Halsey NA, Kelso JM, Wood RA, Hummell DS, Edwards KM, et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organ J. 2016 Sep 16;9(1):32. DOI: 10.1186/s40413-016-0120-5
Ceballos-Liceaga S, Carbajal-Sandoval G, Sánchez-Novoa P, León-Álvarez G, Romualdo-Tello NM, González-Caballero A. Manual de procedimientos estandarizados para la vigilancia epidemiológica de eventos supuestamente atribuibles a la vacunación o inmunización (ESAVI). Dirección General de Epidemiología; 2021. Disponible en: https://epidemiologia.salud.gob.mx/gobmx/salud/documentos/manuales/42_Manual_ESAVI.pdf
Kounis NG, Koniari I, de Gregorio C, Velissaris D, Petalas K, Brinia A, et al. Allergic reactions to current available COVID-19 vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. Vaccines (Basel). 2021;9(3):221. DOI: 10.3390/vaccines9030221
Murphy K, Weaver C. Allergy and allergic diseases. En: Murphy K, Weaver C, editores. Janeway’s immunobiology. 9na ed. New York, USA: Garland Science; 2017. p. 80-103.
Stone CA, Rukasin CRF, Beachkofsky TM, Phillips EJ. Immune-mediated adverse reactions to vaccines. Br J Clin Pharmacol. 2019;85(12):2694-706. DOI: 10.1111/bcp.14112.
Zhang B, Li Q, Shi C, Zhang X. Drug-induced pseudoallergy: a review of the causes and mechanisms. Pharmacology. 2018;101(1-2):104-10. DOI: 10.1159/000479878
Szebeni J. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol. 2014;61(2):163-73. DOI: 10.1016/j.molimm.2014.06.038
Wang H, Wang HS, Liu ZP. Agents that induce pseudo-allergic reaction. Drug Discov Ther. 2011;5(5):211-9. DOI: 10.5582/ddt.2011.v5.5.211
Navinés-Ferrer A, Serrano-Candelas E, Lafuente A, Muñoz-Cano R, Martín M, Gastaminza G. MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia. Sci Rep. 2018;8(1):11628. DOI: 10.1038/s41598-018-29965-8
Caballero ML, Krantz MS, Quirce S, Phillips EJ, Stone CA. Hidden dangers: recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions. J Allergy Clin Immunol Pract. 2021;9(8):2968-82. DOI: 10.1016/j.jaip.2021.03.002
Radice A, Carli G, Macchia D, Farsi A. Allergic reactions after vaccination: translating guidelines into clinical practice. Eur Ann Allergy Clin Immunol. 2019;51(2):51-61. DOI: 10.23822/EurAnnACI.1764-1489.86
Nilsson L, Brockow K, Alm J, Cardona V, Caubet JC, Gomes E, et al. Vaccination and allergy: EAACI position paper, practical aspects. Pediatr Allergy Immunol. 2017;28(7):628-40. DOI: 10.1111/pai.12762
Miller CK, Mendoza JC, Coop CA. Anaphylaxis to MMR vaccine mediated by IgE sensitivity to gelatin. Mil Med. 2020;185(9-10):e1869-71. DOI: 10.1093/milmed/usaa058
Sakai Y, Yamato R, Onuma M, Kikuta T, Watanabe M, Nakayama T. Non-antigenic and low allergic gelatin produced by specific digestion with an enzyme-coupled matrix. Biol Pharm Bull. 1998;21(4):330-4. DOI: 10.1248/bpb.21.330
Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, Valenta R, Hilger C, Hofmaier S, et al. EAACI molecular allergology user’s guide. Pediatr Allergy Immunol. 2016;27(Suppl 23):1-250. DOI: 10.1111/pai.12563
Jiang Y, Yuan IH, Dutille EK, Bailey R, Shaker MS. Preventing iatrogenic gelatin anaphylaxis. Ann Allergy Asthma Immunol. 2019;123(4):366-74. DOI: 10.1016/j.anai.2019.07.017
Kelso JM. Safety of influenza vaccines. Curr Opin Allergy Clin Immunol. 2012;12(4):383-8. DOI: 10.1097/ACI.0b013e328354395d
Houchens N, Hartley S, Commins SP, Claar D, Saint S. Hunting for a Diagnosis. N Engl J Med. 2021;384(5):462-7. DOI: 10.1056/NEJMcps2017588
Uyttebroek A, Sabato V, Bridts CH, De Clerck LS, Ebo DG. Anaphylaxis to succinylated gelatin in a patient with a meat allergy: galactose-(1, 3)-galactose (-gal) as antigenic determinant. J Clin Anesth. 2014;26(7):574-6. DOI: 10.1016/j.jclinane.2014.04.014
Stone CA, Hemler JA, Commins SP, Schuyler AJ, Phillips EJ, Peebles RS, et al. Anaphylaxis after zoster vaccine: Implicating alpha-gal allergy as a possible mechanism. J Allergy Clin Immunol. 2017;139(5):1710-13.e2. DOI: 10.1016/j.jaci.2016.10.037
Caubet JC, Ponvert C. Vaccine Allergy. Immunology and Allergy Clinics of North America. 2014;34(3):597-613.
Zanoni G, Puccetti A, Dolcino M, Simone R, Peretti A, Ferro A, et al. Dextran-specific IgG response in hypersensitivity reactions to measles-mumps-rubella vaccine. J Allergy Clin Immunol. 2008;122(6):1233-5. DOI: 10.1016/j.jaci.2008.09.015
Rouleau I, De Serres G, Drolet JP, Skowronski DM, Ouakki M, Toth E, et al. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. Vaccine. 2013;31(50):5989-96. DOI: 10.1016/j.vaccine.2013.10.033
Rouleau I, De Serres G, Skowronski DM, Drolet JP, Lemire C, Toth E, et al. Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada. Vaccine. 2014;32(28):3480-7. DOI: 10.1016/j.vaccine.2014.04.059.
Bigham M, Copes R. Thiomersal in vaccines: balancing the risk of adverse effects with the risk of vaccine-preventable disease. Drug Saf. 2005;28(2):89-101. DOI: 10.2165/00002018-200528020-00001
Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics. 2004;114(3):793-804. DOI: 10.1542/peds.2004-0434
Zheng W, Dreskin SC. Thimerosal in influenza vaccine: an immediate hypersensitivity reaction. Ann Allergy Asthma Immunol. 2007;99(6):574-5. DOI: 10.1016/S1081-1206(10)60391-2
Kattan JD, Konstantinou GN, Cox AL, Nowak-Węgrzyn A, Gimenez G, Sampson HA, et al. Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow’s milk allergy. J Allergy Clin Immunol. 2011;128(1):215-8. DOI: 10.1016/j.jaci.2011.04.046
Savage JH, Matsui EC, Skripak JM, Wood RA. The natural history of egg allergy. J Allergy Clin Immunol. 2007;120(6):1413-7. DOI: 10.1016/j.jaci.2007.09.040
Boyano-Martínez T, García-Ara C, Díaz-Pena JM, Martín-Esteban M. Prediction of tolerance on the basis of quantification of egg white-specific IgE antibodies in children with egg allergy. J Allergy Clin Immunol. 2002;110(2):304-9. DOI: 10.1067/mai.2002.126081
Merck. M-M-R II: highlights of prescribing information. Merck Sharp & Dohme Corp; 2020. p. 8. Disponible en: https://www.merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_pi.pdf
Kelso JM. Administering influenza vaccine to egg-allergic persons. Expert Rev Vaccines. 2014;13(8):1049-57. DOI: 10.1586/14760584.2014.933079
Baxter DN. Measles immunization in children with a history of egg allergy. Vaccine. 1996;14(2):131-4. DOI: 10.1016/0264-410x(95)00154-s
Committee on Infectious Diseases. Recommendations for Prevention and Control of Influenza in Children, 2020-2021. Pediatrics. 2020;146(4):e2020024588. DOI: 10.1542/peds.2020-024588
Australasian Society of Clinical Immunology and Allergy. ASCIA Guidelines – Vaccination of the egg-allergic individual. Australia: ASCIA; 2017. Disponible en: https://www.allergy.org.au/hp/papers/vaccination-of-the-egg-allergic-individual
Merck. GARDASIL: highlights of prescribing information. Merck Sharp & Dohme Corp; 2011. p. 28 Disponible en: https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Package-Insert---Gardasil.pdf
Merck. RECOMBIVAX HB: highlights of prescribing information. Merck Sharp & Dohme Corp; 2011. p. 10 Disponible en: https://www.merck.com/product/usa/pi_circulars/r/recombivax_hb/recombivax_pi.pdf
Franceschini F, Bottau P, Caimmi S, Crisafulli G, Lucia L, Peroni D, et al. Vaccination in children with allergy to non active vaccine components. Clin Transl Med. 2015;4:3. DOI: 10.1186/s40169-014-0043-0
Fritsche PJ, Helbling A, Ballmer-Weber BK. Vaccine hypersensitivity--update and overview. Swiss Med Wkly. 2010;140(17-18):238-46.
Cullinan P, Brown R, Field A, Hourihane J, Jones M, Kekwick R, et al. Latex allergy. A position paper of the British Society of Allergy and Clinical Immunology. Clin Exp Allergy. 2003;33(11):1484-99. DOI: 10.1046/j.1365-2222.2003.01818.x
Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. 2016;46(7):907-22. DOI: 10.1111/cea.12760
Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 Vaccines. N Engl J Med. 2021;384(7):643-9. DOI: 10.1056/NEJMra2035343
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-16. DOI: 10.1056/NEJMoa2035389.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15. DOI: 10.1056/NEJMoa2034577
Rutkowski K, Mirakian R, Till S, Rutkowski R, Wagner A. Adverse reactions to COVID-19 vaccines: A practical approach. Clin Exp Allergy. 2021;51(6):770-7. DOI: 10.1111/cea.13880
Kennard L, Rutkowski K, Mirakian R, Wagner A. Polyethylene glycol: not just a harmless excipient. J Allergy Clin Immunol Pract. 2018;6:2173. DOI: 10.1016/j.jaip.2018.08.033
Lu IN, Rutkowski K, Kennard L, Nakonechna A, Mirakian R, Wagner A. Polyethylene glycol may be the major allergen in depot medroxy-progesterone acetate. J Allergy Clin Immunol Pract. 2020;8(9):3194-7. DOI: 10.1016/j.jaip.2020.04.057
Stone CA, Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 2019;7(5):1533-40.e8. DOI: 10.1016/j.jaip.2018.12.003
Wenande E, Kroigaard M, Mosbech H, Garvey LH. Polyethylene glycols (PEG) and related structures: overlooked allergens in the perioperative setting. A A Case Rep. 2015;4(5):61-4. DOI: 10.1213/XAA.0000000000000126
Bruusgaard-Mouritsen MA, Johansen JD, Garvey LH. Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients. Clin Exp Allergy. 2021;51(3):463-70. DOI: 10.1111/cea.13822
Institute for Vaccine Safety. Vaccine information: components of vaccines. Johns Hopkins. Bloomberg School of Public Health; 2020. Disponible en: https://www.hopkinsvaccine.org/components.htm
De Serres G, Toth E, Ménard S, Grenier JL, Roussel R, Tremblay M, et al. Oculo-respiratory syndrome after influenza vaccination: trends over four influenza seasons. Vaccine. 2005;23(28):3726-32. DOI: 10.1016/j.vaccine.2005.01.154.
Centers for Disease Control and Prevention (CDC). Syncope after vaccination: United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep. 2008;57(17):457-46018451756
Buettcher M, Heininger U, Braun M, Bonhoeffer J, Halperin S, Heijbel H, et al. Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization in early childhood: case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2007;25(31):5875-81. DOI: 10.1016/j.vaccine.2007.04.061
Cheung A, Choo S, Perrett KP. Vaccine allergy? skin testing and challenge at a tertiary pediatric hospital in Melbourne, Australia. J Allergy Clin Immunol Pract. 2019;7(5):1541-49. DOI: 10.1016/j.jaip.2019.01.025
Zafack JG, De Serres G, Rouleau I, Gariépy MC, Gagnon R, Drolet JP, et al. Clinical Approach Used in Medical Consultations for Allergic-Like Events Following Immunization: Case Series Report in Relation to Practice Guidelines. J Allergy Clin Immunol Pract. 2017;5(3):718-27.e1. DOI: 10.1016/j.jaip.2016.09.048
Wood RA, Setse R, Halsey N; Clinical Immunization Safety Assessment (CISA) Network Hypersensitivity Working Group. Irritant skin test reactions to common vaccines. J Allergy Clin Immunol. 2007;120(2):478-81. DOI: 10.1016/j.jaci.2007.04.035
Wood RA, Berger M, Dreskin SC, Setse R, Engler RJ, Dekker CL, et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics. 2008;122(3):e771-7. DOI: 10.1542/peds.2008-1002
CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46-51. DOI: 10.15585/mmwr.mm7002e1
Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA. 2021;325(8):780-1. DOI: 10.1001/jama.2021.0600
Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101-2. DOI: 10.1001/jama.2021.1967
Sellaturay P, Nasser S, Islam S, Gurugama P, Ewan PW. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. Clin Exp Allergy. 2021;51(6):861-3. DOI: 10.1111/cea.13874
Rasmussen TH, Mortz CG, Georgsen TK, Rasmussen HM, Kjaer HF, Bindslev-Jensen C. Patients with suspected allergic reactions to COVID-19 vaccines can be safely revaccinated after diagnostic work-up. Clin Transl Allergy. 2021;11(5):e12044. DOI: 10.1002/clt2.12044
Paul-Ehrlich-Institut; Robert Koch Institute. How to proceed in case of positive allergy history prior to COVID-19 mRNA vaccination?. Paul-Ehrlich-Institut; 2021. Disponible en: https://www.pei.de/SharedDocs/Downloads/EN/newsroom-en/dossiers/flowchart-allergy-mrna-vaccination.pdf?__blob=publicationFile&v=3
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2022 Revista Alergia México